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Abstract
 
The mechanism of antitumor effect of monoclonal antibodies (mAbs) is not fully understood.
Here we show that coating myeloma cells with anti–syndecan-1 antibody promotes cross-pre-
sentation of cellular antigens by dendritic cells (DCs) to autologous T cells from healthy do-
nors. The tumor cells treated with anti–syndecan-1 or isotype-matched control antibody were
fed to HLA-mismatched monocyte-derived immature DCs. Tumor cell–loaded mature DCs
induced a strong CD8
 
 
 
 T cell response that was specific for the cancer-testis (C-T) antigens
expressed in the tumor. The CD8
 
 
 
 T cells killed peptide-pulsed targets, as well as myeloma tu-
mor cells. Importantly, mAbs-coated tumor-loaded DCs were consistently superior to DCs
loaded with peptides or dying cells for eliciting tumor-specific killer T cells. This enhanced
cross-presentation was not due to enhanced tumor cell uptake or to DC maturation. When
mixtures of NY-Eso-1-positive and -negative myeloma cells were captured by DCs, the anti–
syndecan-1 antibody had to be on the NY-Eso-1-positive cells to elicit NY-Eso-1–specific re-
sponse. Cross-presentation was inhibited by pretreatment of DCs with Fc
 
 
 
 receptor blocking
antibodies. Targeting of mAb-coated tumors to DCs may contribute to the efficacy of tumor-
reactive mAb and offers a new strategy for immunotherapy.
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Introduction
 
MHC class I molecules are generally complexed with pep-
tides derived exclusively from newly synthesized cytosolic
proteins (1). However, CD8
 
 
 
 T cell responses can also be
directed to exogenous cell–associated antigens derived
from tumors, transplants, and virus-infected nonhemato-
poietic cells (2). This requires presentation of these antigens
by bone marrow–derived cells (a process termed cross-pre-
sentation), with dendritic cells (DCs)
 
* 
 
being one of the ma-
jor candidate cell types. DCs can acquire antigen from dy-
ing tumor cells and elicit tumor-specific CD8
 
 
 
 T cell
responses in vitro (3–8). Strategies to optimize cross-pre-
sentation of antigen from tumor cells are of great interest
for immunotherapy of tumors.
Studies in animal tumor models have implicated both
cellular and humoral responses in protective antitumor im-
munity (9). Interest in tumor-specific humoral immunity
has been intensified by certain successes of mAbs in cancer
therapy. The mechanism of antitumor effects of these anti-
bodies is not fully understood. Direct effects on tumor
cells, as well as enhancement of innate effectors (comple-
ment and antibody-dependent cytotoxicity) have been
proposed (10–12). Fc receptors are required for both active
and passive immunity to melanoma, (11) and the protective
effect of therapeutic mAbs in some murine models (12).
Together, these studies point to the importance of Fc-
dependent innate effector mechanisms in the protective ef-
fects of tumor-specific antibodies. However, whether coat-
ing of tumor cells by antibodies also affects antitumor
cellular immunity is not known.
Here we show that coating of tumor cells with antitu-
mor mAbs leads to enhanced cross-presentation of tumor-
derived cellular antigens and generation of tumor specific–
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C-T, cancer-testis; DC, dendritic cell;
Fc
 
 
 
R, Fc
 
 
 
 receptor. 
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killer T cells by DCs. This effect is dependent on Fc
 
 
 
 re-
ceptors (Fc
 
 
 
Rs) on the DCs, but is exerted at a step after
the uptake of tumor cells by DCs.
 
Materials and Methods
 
Myeloma Cell Lines.
 
Myeloma cell lines were obtained from
American Type Culture Collection (U266, RPMI 8226), or pro-
vided by J. Epstein, Arkansas Cancer Center, Little Rock, AR;
cag, arp, ark cells). HLA A2.1 status on cell lines was assessed by
serotyping. All cell lines were grown in RPMI 1640/10–20%
FCS/glutamine/gentamicin.
 
Expression of Cancer-Testis Antigens.
 
The expression of a panel
of cancer-testis (C-T) antigens (MAGE1, MAGE3, MAGE4,
MAGE10, CT-7, LAGE-1, and NY-Eso-1) by myeloma cells
was examined using RT-PCR, as described previously (13).
 
Generation of Dying/Antibody-Coated Tumor Cells.
 
Tumor
cells were killed by repeated freeze thaw cycles (necrosis) or by 
 
 
 
irradiation (30 Gy) (apoptosis). The induction of apoptosis was
monitored using staining with Annexin V-FITC. For antibody
coating, tumor cells (10
 
7
 
 cells per milliliter) were incubated with
anti–syndecan-1 antibody (14) (1 
 
 
 
g/ml, B-B4; Serotec) or isotype
(IgG1) control, for 30 min at 4
 
 
 
C. Syndecan-1 is a heparan sulfate
proteoglycan highly expressed on myeloma cells. After antibody
coating, cells were washed, irradiated with 3 Gy, and immediately
added to immature DCs as live (Annexin V-negative) cells. To de-
termine if antibody coating enhanced presentation of antigens from
dying cells, tumor cells were killed either by 
 
 
 
-irradiation (apopto-
sis) or freeze thaw (necrosis) as above, and then treated with anti–
syndecan-1 or isotype control antibody as described above, or left
untreated, before feeding to DCs at DC/tumor ratio of 1:1.
 
Generation and Loading of DCs with Tumor Antigens.
 
DCs
were generated as described previously (15), by culture of plastic
adherent blood mononuclear cells, obtained from leucocyte con-
centrates, or whole blood of A2.1
 
 
 
ve healthy donors, in GM-
CSF (Immunex) and IL-4 (R&D Systems). The nonadherent
blood cells were used as a source of T cells. On day 5 or 6 of cul-
ture, the immature DCs were fed in 96-well plates with apop-
totic, necrotic, or live antibody coated HLA A2.1-negative tu-
mor cells at a ratio of 1:1 and then 4–12 h later, a cytokine
cocktail consisting of IL-1
 
 
 
 (10 ng/ml), IL-6 (1,000 U/ml),
TNF-
 
 
 
 (10 ng/ml), and PGE
 
2
 
 (1 
 
 
 
g/ml) was added to induce
maturation (16, 17). As controls, some mature DCs were pulsed
for 2 h with 1 
 
 
 
M HLA A2.1-restricted peptides from MAGE-3
(271–279; FLWGPRALV) and NY-Eso-1 (157–167; SLLM-
WITQCFL). For some experiments, DCs were pretreated with a
cocktail of anti–human Fc receptor blocking anti-CD16 (clone
 
3G8) and CD32 (clone IV.3) antibodies (both at 10 
 
 
 
g/ml for 60
min; Medarex), before tumor cell feed. For some experiments,
DCs were fed with a mixture of antibody-treated and untreated
tumor cells, differing in the expression of tumor antigens.
 
Evaluation of Tumor Cell Uptake.
 
To evaluate phagocytosis of
tumor cells by DCs, tumor cells were dyed red with PKH26
(Sigma-Aldrich) before cell death or antibody coating, and im-
mature DCs were stained green with PKH67 (Sigma-Aldrich)
before coculture with tumor for 0–16 h at 4
 
 
 
C or 37
 
 
 
C (5).
Phagocytosis was monitored by flow cytometry as double-posi-
tive cells. Tumor cell uptake was also evaluated by applying tu-
mor cell–loaded DCs to alcian blue coated slides for two color
fluorescence microscopy using an Olympus epifluorescence mi-
croscope. DCs were stained with anti-CD11c and tumor cells
were stained with an antibody for C-T antigen, CT-7 (a gift of
A. Jungbluth, Ludwig Institute, New York, NY). The motorized
stage allowed 0.5-mm optical sections with a cooled CCD cam-
era (Hammatsu) and Metamorph software (Universal Imaging
Corp.).
 
Stimulation of T Cells.
 
Antigen loaded or unpulsed DCs were
cocultured in 96-well round-bottomed microtest plates with au-
tologous nonadherent cells at a ratio of 1:30 in 0.2 ml of 5%
pooled human serum. As controls, irradiated (3 Gy) antibody/
isotype treated tumor cells were also used to present antigen.
The culture media was supplemented with recombinant IL-2
(50 U/ml) on days 4 and 7 of culture. At 1 wk, cultures were re-
stimulated with the identical APCs as the initial stimulation. For
some experiments, DCs loaded with tumor cells were purified
from the DC-tumor mixtures after initial coculture for 4 h, us-
ing anti-CD11c-coupled magnetic beads (Miltenyi Biotech).
The DCs were matured before their use as APCs. For some ex-
periments, DCs loaded with tumor cells were cultured in trans-
well inserts, physically separated from autologous T cells and un-
pulsed DCs.
 
Evaluation of Antigen-specific T Cell Response.
 
Antigen-spe-
cific T cell response against defined HLA A
 
*
 
0201-restricted pep-
tide epitopes from MAGE-3 and NY-Eso-1 was determined
using IFN-
 
 
 
 enzyme linked immunospot (ELISPOT) and
cytotoxicity assays, after 2 wk of culture with tumor/peptide
loaded DCs. For the ELISPOT assay, autologous mature DCs
pulsed with 1 
 
 
 
M of specific (MAGE-3, NY-Eso-1) or irrelevant
(HIV-gag) peptide were used as APCs at ratio of 1:30, and spot-
forming cells were quantified after overnight culture as described
previously (15). For evaluation of antigen-specific killers, T2 cells
pulsed with 1 
 
 
 
M of specific (MAGE-3, NY-Eso-1) peptide
were used as targets in a standard 5 h 
 
51
 
Cr release assay. Other tar-
gets were HLA A
 
*
 
0201 
 
 
 
ve (U266 cells) or –ve (ark cells) my-
 
Table I.
 
Expression of C-T Antigens in Myeloma Cells by RT-PCR
 
C-T Antigen
Cells NY Eso-1 LAGE-1 MAGE-1 MAGE-3 MAGE-4 MAGE-10 CT-7
arp
 
                 
 
ark
 
                        
 
cag
 
                           
 
U266
 
                   
 
/
 
    
 
RPMI8226
 
 
 
/
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eloma cells known to express both MAGE-3 and NY-Eso-1, and
K562 cells to monitor NK cell–mediated lysis.
 
Results
 
Myeloma Cells Express Several C-T Antigens.
 
The ex-
pression of several members of C-T antigen family by my-
eloma cell lines was evaluated by RT-PCR. All cell lines
tested expressed at least one member of this family (Table I).
 
Immature DCs Acquire Cellular Antigens from Dying or An-
tibody-coated Tumor Cells but Inflammatory Cytokines Are Re-
quired for Full DC Maturation.
 
We used 2 HLA A2.1-neg-
ative cell lines (cag, arp) expressing both MAGE-3 and
NY-ESO-1 (cag cells) or MAGE-3 alone (arp cells), as
Figure 1. Uptake of tumor cells by DCs. Myeloma cells were labeled with dye (PKH26) and either stained with anti–syndecan-1 antibody (mAb), iso-
type control antibody, or left unstained. Tumor cells were irradiated (3 Gy) just before coculture with dye (PKH67) labeled DCs at 4 C or 37 C, and the
percent of double-positive DCs (top right of each panel) analyzed by flow cytometry.
Figure 2. Phagocytosis of
mAb-coated tumor does not
trigger extensive DC maturation.
Monocyte-derived DCs at day 6
of culture were cultured in me-
dia alone, with inflammatory cy-
tokine cocktail, or with tumor
cells pretreated with anti–synde-
can-1 or isotype control anti-
body. After 1 d of culture, the
cells were stained with anti-HLA
DR (FITC/PE) and one of the
following antibodies (anti-
CD80, CD86, CD83, CD40, and
CD25). Percentage of HLA-DR
 ve DCs expressing CD83,
CD80, CD86, CD40, or CD25
(top right of each panel) were
quantified by flow cytometry. 
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sources of defined C-T antigens to elicit HLA A
 
*
 
0201-
restricted peptide-specific T cells in vitro. Both cell lines
expressed high levels of syndecan-1, and binding of anti-syn-
decan antibody did not induce apoptosis (data not shown).
The myeloma cells were induced to undergo apoptosis by
high dose (30 Gy) 
 
 
 
 irradiation, necrosis by repeated freeze
thaw cycles, or treated with anti–syndecan-1 antibody/iso-
type, as live, low dose (3 Gy) 
 
 
 
-irradiated cells. Myeloma
cells were then fed to immature DCs from healthy donors.
Phagocytosis studies performed using tumor cells and DCs
labeled with different color fluorochromes indicated that
label from anti–syndecan-1, isotype control antibody
treated, or untreated tumor cells was taken up by DCs
upon 2–20 h of coculture at 37
 
 
 
C (but not at 4
 
 
 
C) with
similar efficiency (Fig. 1). Uptake of tumor cells was also
verified using confocal microscopy after staining for tumor
Figure 3. Generation of cancer testis an-
tigen-specific IFN- –producing T cells by
DCs. (A) Generation of MAGE-3 or NY-
Eso-1 specific T cells by peptide-pulsed or
tumor cell–loaded DCs. HLA A2.1  ve
myeloma cells (cag, arp) were killed either
by  -irradiation (30 Gy) (apoptosis), freeze
thaw cycles (necrosis), or coated with anti–
syndecan-1 antibody (mAb)/isotype con-
trol, irradiated (3 Gy), and added to HLA
A2.1  ve immature DCs as live (annexin
V-negative) cells. DCs were matured using
cytokine cocktail. Autologous T cells were
stimulated with mature peptide-pulsed or
tumor cell–loaded DCs, or tumor cells
alone. After two stimulations, the number
of HLA A*0201-restricted MAGE3/NY-
Eso-1 peptide specific IFN- –producing
cells were quantified with an ELISPOT as-
say, using peptide pulsed autologous DCs as
APCs. (B) Summary of MAGE3/NY-Eso-1–
specific T cells elicited in five experiments,
using DCs loaded with dying (apoptotic/
necrotic) or antibody-treated (anti–synde-
can-1 mAb/isotype) myeloma cells (arp
cells, MAGE3 , NY-Eso-1 –ve). (C) Stim-
ulation using CD11c  DCs from DC-tumor
cocultures. CD11c  DCs were purified us-
ing magnetic beads from 4-h cocultures of
HLA A2.1  ve DCs with dying HLA
A2.1 ve myeloma (cag) cells (apoptosis/
necrosis, as described earlier); or coated
with anti–syndecan-1 antibody/isotype.
These DCs were then matured using cyto-
kine cocktail and used as APCs to either di-
rectly stimulate autologous T cells, or in
transwell cultures separated from T cells and
unpulsed DCs. After two stimulations, HLA
A*0201-restricted MAGE-3 or NY-Eso-1
peptide-specific T cells were quantified by
ELISPOT using autologous peptide-pulsed
DCs as APCs. Data are representative of
two similar experiments. 
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cells with an antibody to the CT-7 tumor antigen (data not
shown). Therefore the coating with anti–syndecan-1 anti-
body was not required for tumor cell uptake in this system.
Ligation of Fc
 
 
 
R is known to induce the maturation of
mouse DCs. In our system however, the uptake of anti-
body treated (both anti–syndecan-1 or isotype control), or
untreated tumor cells was associated with partial, but
equivalent phenotypic maturation of DCs, as measured by
a slight increase in the surface expression of CD83, and
considerable increases in CD80 and CD86. However, up-
regulation of HLA-DR, CD40, and CD25 was not noted,
as with DCs matured using inflammatory cytokines (Fig.
2). However these DCs could be fully matured by the ad-
dition of inflammatory cytokine cocktail after tumor cell
uptake (data not shown). Therefore the anti–syndecan-1
antibody does not detectably influence DC uptake of my-
eloma cells or DC maturation.
 
Uptake of Antibody-coated Tumor Cells Leads to Strong
Cross-Presentation for Antigen-specific T Cell Responses, Includ-
ing T Cells Lytic for HLA A2.1
 
 
 
 Myeloma Targets.
 
After
phagocytosis and ex vivo maturation using cytokine cock-
tail, the tumor-loaded, peptide-pulsed, or unpulsed DCs, as
well as tumor cells alone, were used as APCs to stimulate T
cells in culture. No T cell reactivity to either MAGE3 or
NY-Eso-1 peptide was noted at baseline before in vitro ex-
pansion in any subject (data not shown). However, DCs
 
loaded with apoptotic-, necrotic-, or antibody-coated my-
eloma cells expanded C-T antigen-specific T cells using
two cycles of stimulation in vitro (Fig. 3 A). If the tumor
expressed both MAGE-3 and NY-Eso-1 (cag cells), then
both MAGE-3 and NY-Eso-1–specific T cells developed.
In contrast, expansion of only MAGE-3 but not NY-Eso-
1–specific T cells was seen using DCs loaded with arp cells,
consistent with the pattern of antigen expression on these
cells. Peptide-pulsed DCs also led to the expansion of pep-
tide-specific T cells, while no expansion was seen using tu-
mor cells alone. The antigen-specific T cell responses were
lost after depletion with anti-CD8 antibody before the
ELISPOT, indicating the CD8
 
 
 
 nature of the IFN-
 
 
 
–
secreting cells (data not shown).
In experiments with five consecutive donors, the gener-
ation of tumor-specific T cells was the greatest using DCs
loaded with antibody-coated tumor cells (5/5 donors),
higher than the responses observed using DCs loaded with
only dying cells (3/5 experiments; Fig. 3 B). Thus antibody
coating of tumor cells enhances the cross-presentation of
cellular antigens after tumor cell uptake by DCs.
To examine the possibility that contaminating cells in the
DC-tumor cocultures led to T cell expansion, we purified
CD11c
 
 
 
 DCs from the DC-myeloma mixtures by positive
selection, and then used CD11c
 
 
 
 or CD11c
 
 
 
ve fractions as
APCs. The CD11c purified DCs expanded antigen specific
Figure 4. Generation of tumor-specific killer T
cells. (A) Generation of killer T cells using peptide-
pulsed or tumor cell–loaded DCs. T cells from ex-
periment in Fig. 3 A were tested for killing of T2
cells pulsed with 10  M HLA A*0201-restricted
MAGE3/ NY-Eso-1 peptide or HLA A*0201-pos-
itive (U266) or -negative (ark) myeloma cells, at a
E/T ratio of 20:1, with a 5 h 51Cr release assay. Ly-
sis of K562 cells (as control) was  10% (data not
shown). (B) Summary of experiments on three do-
nors using DCs loaded with dying (apoptotic/ne-
crotic) or antibody-treated (anti–syndecan-1 mAb/
isotype) myeloma cells (arp cells: MAGE-3  ve,
NY-Eso-1 –ve). 
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T cells (Fig. 3 C). No T cell expansion was seen with the
CD11c 
 
 
 
ve fraction (data not shown). To examine if solu-
ble factors/peptides generated in these cultures could lead
to T cell expansion, we cultured these tumor cell–loaded
DCs in transwell inserts, physically separated from mixtures
of T cells and unpulsed DCs. No expansion of antigen-spe-
cific T cells was seen in these cultures. In summary, activa-
tion of tumor-specific T cells requires direct contact of T
cells with the tumor-loaded DCs (Fig. 3 C).
T cells elicited using mAb tumor–loaded DCs efficiently
killed not only peptide pulsed targets, but also killed tumor
cells HLA matched to DCs (Fig. 4 A and B). In contrast, T
cells elicited using peptide-pulsed DCs only killed peptide
pulsed targets, but not HLA A2.1
 
 
 
 myeloma cells express-
ing these antigens (Fig. 4 A). The killing of tumor cells was
inhibited by preincubation of targets with anti-MHC I, but
not anti-MHC II (data not shown), consistent with the re-
sponse being due to CD8
 
 
 
 T cells and specific for MHC
class I binding peptides. Again, the generation of tumor-
specific killer T cells was higher and more consistent using
DCs loaded with antibody- coated cells (3/3 donors) than
using dying cell loaded DCs (2/3 donors; Fig. 4 B). Thus
DCs loaded with antibody-coated tumor cells are superior
to peptide pulsed DCs or DCs loaded with dying cells to
stimulate tumor-specific killer T cells.
 
mAbs also Lead to Enhanced Cross-Presentation of Antigen
from Tumor Cells that Have Been Induced to Undergo Apopto-
sis.
 
In the experiments described above, we cocultured
DCs with live antibody-coated tumor cells after low dose
(3 Gy) irradiation. However, several studies have shown
that DCs can cross-present antigen from apoptotic or ne-
crotic tumor cells. Therefore, we next examined if anti-
body coating also enhanced cross-presentation of antigen
from dying cells. We first confirmed the expression of syn-
decan-1 on tumor cells rendered apoptotic after 
 
 
 
-irradia-
tion, by double staining for Annexin V and CD138 (data
not shown). Next, we fed DCs with apoptotic or necrotic
tumor cells that had been stained with anti–syndecan-1 an-
tibody, isotype control, or left unstained. These DCs were
then matured using an inflammatory cytokine cocktail and
used as APCs to stimulate autologous T cells. The DCs that
were fed with antibody-coated apoptotic tumor cells ex-
panded antigen-specific T cells more efficiently relative to
DCs fed with apoptotic cells alone (Fig. 5 A). No enhance-
Figure 5. Effects of antitumor antibodies on cross pre-
sentation of cellular antigens from dying tumor cells. (A)
HLA A2.1 ve myeloma cells were killed either by  -irra-
diation (apoptosis) or freeze thaw (necrosis), and either left
untreated, or coated with anti–syndecan-1 antibody (mAb)
or isotype. HLA A2.1  DCs were fed with tumor cells,
matured with cytokine cocktail and then used to stimulate
autologous T cells. After two stimulations, generation of
HLA A*0201-restricted MAGE-3 or NY-Eso-1 peptide-
specific T cells was quantified in a 16 h ELISPOT using
autologous peptide-pulsed mature DCs as APCs. (B) T
cells from experiment in A were tested for killing of T2
cells pulsed with HLA A*0201-restricted MAGE3/NY-
Eso-1 peptide or HLA A*0201-positive (U266) or -nega-
tive (ark) myeloma cells, at a E/T ratio of 20:1, with a
standard 5 h 51Cr release assay. 
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ment of presentation of necrotic cells was observed by anti-
body-mediated targeting, which is likely due to the lack of
effective binding of the antibody to necrotic fragments. T
cells expanded using DCs loaded with antibody-coated ap-
optotic cells were also superior at killing peptide-pulsed or
tumor cell targets (Fig. 5 B). Thus antibody coating of tu-
mor cells also leads to enhanced cross-presentation of dying
cells by DCs.
 
Antibody Enhanced Cross-Presentation Depends on Fc Recep-
tors, but at a Step Beyond Tumor Cell Uptake.
 
To examine
the role of antibody and Fc
 
 
 
R in the cross-presentation of
antigens by DCs, DCs were first fed with a mixture of anti-
gen (NY-Eso-1)-positive (cag cells) and negative (arp cells)
tumors. The tumor cells were internalized similarly with or
without antibody coating, implying substantial direct rec-
ognition of tumor cells by DCs. However, NY-Eso-1–spe-
cific T cells were efficiently expanded in these cultures only
if the NY-Eso-1-positive tumor cells (cag cells) were
coated with anti–syndecan-1 antibody (Fig. 6 A). There-
fore, antibody coating directly promotes the cross-presen-
tation of tumor cells.
Preincubation of DCs with a cocktail of Fc receptor
blocking antibodies (anti-CD16 plus CD32) also signifi-
cantly inhibited the generation of antigen-specific IFN-
 
 
 
–
producing T cells after uptake of tumor cells (Fig. 6 B), al-
though the uptake of tumor cells was not blocked (data not
shown). Likewise, the generation of antigen-specific killer
T cells was also inhibited in these cultures (data not
shown). Culture of DCs and T cells in heat-inactivated se-
rum to inactivate complement, did not inhibit the genera-
tion of tumor-specific T cells (data not shown). Thus en-
hanced cross-presentation of mAb-coated tumor cells is
dependent on Fc receptor mediated interactions, that act at
a step subsequent to standard opsonization or uptake.
 
Discussion
Cross-presentation of cellular antigens is of special inter-
est in tumor immunology, as tumors themselves are poor
APCs (2). Recent studies have shown that DCs can acquire
cellular antigen from dying tumor cells and expand tumor
reactive CD8  killer T cells in vitro (3–8). Our studies
now demonstrate that cross-presentation of cellular anti-
gens by human DCs is enhanced by mAb-mediated target-
ing. DCs, positively selected after just 4-h coculture with
live mAb treated tumor cells, are able to present tumor an-
tigen with superior efficiency than DCs loaded with dying
cells or defined peptides.
Enhanced cross-presentation of antibody-coated tumor
cells is dependent on Fc R-mediated interactions and in-
hibited by preincubation of DCs with Fc R blocking anti-
bodies. Increased presentation is not simply explained by
increased phagocytosis of mAb-treated tumor cells. Thus,
the uptake of tumor cells treated with isotype control anti-
body is comparable to the cells treated with anti-syndecan,
yet the former are presented poorly under identical condi-
tions. Indeed, when DCs are fed with a mixture of antigen-
positive and -negative cells, efficient generation of antigen-
Figure 6. Cross-presentation requirements beyond
tumor cell uptake. (A) Antibody enhances cross-pre-
sentation only when coating the tumor antigen-
expressing myeloma cell. arp (NY-Eso-1 ve) and cag
(NY-Eso-1  ve) cells were treated with anti–synde-
can-1 or isotype control antibody and fed to HLA A2.1
 ve DCs, either alone, or together, at DC/tumor ratio
of 1:1. Tumor cell–loaded DCs (after maturation with
cytokine cocktail), were used to stimulate autologous T
cells. After two stimulations, the number of peptide-
specific T cells was quantified using peptide-pulsed
DCs as APCs in an ELISPOT assay. (B) Fc R block-
ing antibodies decrease cross-presentation. DCs were
pretreated with anti-Fc R blocking antibodies
(CD16 CD32) or with isotype controls, before feed-
ing tumor cells treated with anti-syndecan (mAb-Tum)
or isotype (Iso-Tum) control antibody, as described in
the legend to Fig. 3 A. Antigen-specific T cells were
quantified after two stimulations, in an ELISPOT assay
using peptide-pulsed DCs as APCs.132 mAbs Enhance Cross-Presentation by Dendritic Cells
specific T cells occurs only when the cells that express the
antigen are coated with the mAb.
Although uptake of antigen as immune complexes or
Fc R targeted liposomes delivers a maturation signal to
murine DCs, we were unable to show a difference in phe-
notypic maturation between DCs fed with antibody-
treated or untreated tumor cells (18, 19). Taken together,
our data suggest that the enhanced cross-presentation of
antibody-coated tumor cells by DCs is primarily due to en-
hanced efficiency of cross-presentation for antigen via
Fc R. Thus while DCs may be efficient at phagocytosing
myeloma cells, efficient cross-presentation of the phagocy-
tosed antigen by DCs may depend on the specific receptors
involved in tumor antigen uptake. This result is reminis-
cent of the findings of Albert et al., who found that mono-
cytes could phagocytose apoptotic cells as well as immature
DCs, and expressed high levels of MHC I, but only DCs
could cross-present the cell-associated antigen (20). En-
hancement of cross-presentation observed here may be due
to novel pathways of antigen processing for FcR-mediated
uptake (21) or FcR-mediated signaling (22). Indeed, sev-
eral studies have shown efficient Fc R-mediated uptake
and presentation of immune complexes in murine and hu-
man APCs including DCs (18, 23–28).
Whole (either autologous or allogeneic) tumor cells are
an attractive source of antigen to load DCs simultaneously
with multiple tumor-specific epitopes for immunotherapy.
Our findings that DCs loaded with antibody-coated cells
are superior to both peptide-pulsed, as well as dying cell-
loaded DCs, provides a novel and potentially more effec-
tive antigen loading strategy for DC immunotherapy and
the generation of tumor-specific killer T cells for adoptive
transfer. T cells elicited using peptide-pulsed DCs killed
peptide pulsed targets, but not tumor cells. Lack of tumor
cell killing by some (specially MAGE-3) peptide-specific T
cells may relate to the lack of processing and presentation
of this epitope by tumor cells (29). Importantly, T cells
elicited using mAb-tumor loaded DCs were superior to
peptide-loaded DCs not only for killing of peptide-pulsed
targets but also lysed HLA-matched tumor cells. The
mechanism for eliciting superior antigen-specific lytic ef-
fectors after mAb-tumor loaded DCs is not known, and
may be due to the elicitation of tumor-specific CD4  T
cells, the polyepitope nature of the response or the unique
efficiency of Fc R-mediated intracellular antigen process-
ing in DCs, as compared with loading with preprocessed
peptide (21, 25, 30).
Antitumor effects of mAbs in cancer are thought to be
mediated by direct effects on cancer cells, as well as en-
hancement of innate effectors. Binding of antibodies to tu-
mors cells can sensitize them for complement or antibody-
dependent cytotoxicity (10). However the impact of this
therapy on T cell immunity is unclear. In some tumor
models, both CD8  T cells and functional Fc Rs were
shown to be important for mAb-mediated eradication of
established tumor (31, 32). Increase in T cell infiltration at
the tumor site has also been observed in some human mAb
trials, however specificity of the T cell response was not
determined (33). Our findings suggest that mAb therapy
may also promote the induction of antigen-specific CD8 
T cell responses. These data may also allow the application
of mAbs to settings wherein such therapy may not be clini-
cally feasible. For example, selective targeting of anti–syn-
decan-1 to myeloma cells in vivo is limited by the fact that
this molecule is expressed on nonhematopoietic cells. Our
data now suggest a strategy for ex vivo targeting of this
molecule on myeloma tumor cells to DCs.
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